Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene — a gene that can cause cancer — that may play an important role in colon cancer. Researchers also showed how this ...

The regulatory success of KRAS-targeting therapies marked a watershed moment, but there is room for improvement in the real world.

The KRAS G12C mutation is found in approximately 3% of all colorectal cancer cases and 1% to 2% of pancreatic adenocarcinoma cases, according to Hao Xie, MD, PhD, a medical oncologist at Mayo Clinic ...

Lumakras plus Vectibix improved overall survival and response rates in KRAS G12C-mutated metastatic colorectal cancer, despite not achieving statistical significance. The combination showed a 30% ...

July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...

Direct multi-KRAS inhibitors, QTX3034 and QTX3544, exhibit potent activity against established and novel resistance mechanisms to ...

Analysis of tumor microenvironmental features of primary and synchronous liver metastases from patients with colorectal cancer using a deep learning algorithm. Real-world analysis of the impact of ...

Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer. Among patients with heavily pretreated patients with KRAS ...

THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS ® (sotorasib) in combination with Vectibix ® ...

Bottom Line: Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C ...